Phase Genomics Advances Precision Oncology with OncoTerra ™, a New Ultra-Long Range Sequencing-Powered Platform | Business

0


SEATTLE – (BUSINESS WIRE) – January 5, 2022–

Phase Genomics, Inc., a biotechnology company at the forefront of advancing next-generation sequencing (NGS) solutions for genome assembly and analysis, today announced the launch of its new platform for precision oncology.

The OncoTerra platform implements a fast and cost-effective alternative to current cytogenomic analysis tools while unlocking insights even in the most difficult sample types. The platform offers genome-wide detection of a wide range of chromosomal abnormalities without the need for actively dividing cells, high molecular weight DNA extraction or high starting cell volume , all in one test. In addition, it is particularly effective on formalin fixed and paraffin-embedded (FFPE) samples, allowing a multitude of new applications in oncology.

“Capturing structural genomic information in previously inaccessible sample types and transforming it into actionable information relevant to human health is an extremely powerful capability of our technology,” said Ivan Liachko, Founder and CEO of Phase Genomics. “Access to the vast amounts of clinical information that has been locked away in FFPE samples will be of great benefit to translational researchers in the field of oncology.”

FFPE samples currently represent> 90% of biopsy samples, or over 2 billion samples. The OncoTerra platform offers the unique ability to unlock the cytogenomic information stored in these samples, allowing researchers to collect more data than ever before, potentially leading to advances in clinical care and diagnostics.

The platform is powered by Phase Genomics ultra-long range sequencing technology which captures physical proximity data from DNA sequences in the genome. This data is then analyzed through proprietary machine learning tools to detect various chromosome aberrations and rearrangements, including tumorigenic rearrangements, which cause and characterize diseases.

The Phase Genomics platform is intended for research only and is not intended for use in diagnostic procedures. More information on the platform is available here.

Watch a webinar, hosted by Phase Genomics to learn more about this technology and follow Phase Genomics on Twitter for the latest news and information.

ABOUT PHASE GENOMICS

Phase Genomics applies Hi-C and other proximity ligation methods to enable chromosome-wide genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and architecture. of the genome. They offer a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples, as well as genome assembly and analysis software. and industry-leading metagenomes.

Headquartered in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company’s mission is to equip scientists with genomic tools that accelerate revolutionary discoveries.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220105005839/en/

Eric Schudiske ([email protected])

KEYWORD: UNITED STATES NORTH AMERICA WASHINGTON

INDUSTRY KEYWORD: SOFTWARE RESEARCH DATA MANAGEMENT ONCOLOGY TECHNOLOGY UNIVERSITY OF GENETICS EDUCATION SCIENCE BIOTECHNOLOGY OTHER TECHNOLOGY HEALTH OTHER SCIENCE

SOURCE: Phase Genomics, Inc.

Copyright Business Wire 2022.

PUB: 05/01/2022 12:31 / DISC: 05/01/2022 12:32

http://www.businesswire.com/news/home/20220105005839/en

Copyright Business Wire 2022.



Share.

Comments are closed.